ORIENT PHARMA CO., LTD.

Highlights Orient Pharma Co., Ltd.

Equities

4166

TW0004166004

End-of-day quote Taipei Exchange Other stock markets 03:30:00 27/05/2024 am IST			5-day change	1st Jan Change
26.8 ^TWD	-2.72%		-4.11%	+34.00%

15/04	Orient Pharma Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	CI
2023	Orient Pharma Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Orient Pharma Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	15/04	CI
Orient Pharma Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023	11/23/11	CI
Orient Pharma Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022	17/23/17	CI
Orient Pharma Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2022	11/22/11	CI
Orient Pharma Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2021	31/22/31	CI
Orient Pharma Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2021	03/21/03	CI
Orient Pharma Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2020	15/21/15	CI
Orient Pharma Co., Ltd. Reports Earnings Results for the Third Quarter Ended September 30, 2020	08/21/08	CI
Orient Pharma Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2020	12/20/12	CI
Orient Pharma Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2019	21/20/21	CI
Orient Pharma Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2019	13/19/13	CI
Orient Pharma Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2018	26/19/26	CI
DURECT Corporation Announces Selection with Orient Pharma Co. of Lead Formulation for ORADUR(R)-Methylphenidate	01/13/01	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

+39.41% on our US portfolio vs. 25.67% on the S&P 500 net Total Return

Replicate our performance

fermer